



Annual General and Special Meeting

1:30PM, June 26, 2026

Table of Contents

NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS	3
MANAGEMENT INFORMATION CIRCULAR	4
PART 1 – PROXIES	4
MANAGEMENT SOLICITATION	4
WHO CAN VOTE?	4
METHODS OF VOTING	4
WHAT IS OUR QUORUM?	6
HOW A VOTE IS PASSED.....	7
PART 2 – AUTHORIZED CAPITAL, VOTING SHARES AND PRINCIPAL HOLDERS THEREOF	7
PART 3 – MATTERS TO BE ACTED UPON AT THE AGSM	7
FINANCIAL STATEMENTS	7
ELECTION OF DIRECTORS	7
APPOINTMENT OF THE AUDITOR	9
APPROVAL OF DEBT SETTLEMENT	10
OTHER BUSINESS.....	12
PART 4 – INFORMATION CONCERNING NOVRA	12
DIRECTOR AND EXECUTIVE COMPENSATION	12
SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS	15
INDEBTEDNESS OF DIRECTORS AND OFFICERS.....	16
INTEREST OF INSIDERS IN MATERIAL TRANSACTIONS.....	16
INTEREST OF CERTAIN PERSONS IN MATTERS TO BE ACTED UPON	16
MANAGEMENT CONTRACTS.....	16
DIVERSITY DISCLOSURE.....	17
ADDITIONAL INFORMATION	17
PART 5 – AUDIT COMMITTEE INFORMATION.....	17
AUDIT COMMITTEE CHARTER.....	17
AUDIT COMMITTEE COMPOSITION AND BACKGROUND.....	17
RELEVANT EDUCATION AND EXPERIENCE	18
EXTERNAL AUDITOR SERVICE FEES	19
PART 6 – CORPORATE GOVERNANCE	19
BOARD APPROVAL	21
APPENDIX A - CHARTER FOR THE AUDIT COMMITTEE	22

NOVRA TECHNOLOGIES INC.

NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS

NOTICE IS HEREBY GIVEN that the Annual General and Special Meeting (the "AGSM") of Shareholders of **NOVRA TECHNOLOGIES INC.** (hereinafter called the "Company" or "Novra") will be held in Novra's offices at 210- 100 Innovation Drive, Winnipeg, Manitoba, Canada on the 26th day of June 2026 at the hour of 1:30 p.m. (Central Daylight Time), for the following purposes:

1. To receive the audited Consolidated Financial Statements of the Company for the fiscal year ended December 31, 2025, and the auditor's report thereon;
2. To elect Directors of the Company for the ensuing year;
3. To re-appoint Baker Tilly HMA LLP as the Company's independent auditors for the ensuing year and to authorize the Board of Directors to fix their remuneration; and
4. To consider and, if deemed advisable, pass a resolution approving the settlement of US \$3,200,000, or \$4,352,000 CAD based on an exchange rate of \$1.36, of the Company's convertible notes through the issuance of 12,800,000 common shares of the Company at a deemed stock price \$0.34 CAD per share.
5. To transact such further or other business as may properly come before the AGSM or any adjournment thereof.

The accompanying Management Information Circular provides further details on the matters proposed to be put before the AGSM. Further it provides instructions on the various methods that a shareholder of the Company can use to have their shares voted at the meeting including instructions regarding voting in person, by mail, by internet or by phone.

The Board of Directors has set the close of business on May 6, 2026, as the record date for determining those shareholders entitled to receive notice of, and to vote at, the AGSM.

DATED at Winnipeg, Manitoba, this 22nd day of May 2026.

BY ORDER OF THE BOARD OF DIRECTORS

(signed) "Harris Liontas"

CEO and Director

NOVRA TECHNOLOGIES INC.

MANAGEMENT INFORMATION CIRCULAR

PART 1 – PROXIES

MANAGEMENT SOLICITATION

This Management Information Circular (“**Circular**”) is provided with the solicitation of proxies by the management of Novra Technologies Inc. (herein referred as “**Novra**”, “**we**”, “**us**” or “**our**”) for use at the Annual General and Special Meeting (“**AGSM**”) of the shareholders of Novra that is to be held on June 26th, 2026 at 1:30 p.m. (Central Daylight Time) at 210 - 100 Innovation Drive, Winnipeg, Manitoba, Canada and any adjournment thereof, for the purpose set out in the Notice of Annual General and Special Meeting.

Solicitation of proxies will be primarily by mail; but, some proxies may be solicited at a nominal cost personally or by telephone, facsimile or other electronic means by executives or directors of Novra. The cost of solicitation will be borne by Novra. Except as otherwise stated, the information contained herein is given as of May 22nd, 2026.

WHO CAN VOTE?

All shareholders of record on May 6, 2026.

METHODS OF VOTING

Registered Shareholder Voting	Beneficial Shareholder Voting
<p>You are a registered holder if your common shares are in your name and you have a physical share certificate in your possession or you have a book entry only statement from our transfer agent (Computershare) indicating that the shares are registered in your name.</p> <p><u>Voting Options</u></p> <ol style="list-style-type: none">1. In person at the AGSM (see below)2. By proxy (see below)3. By telephone (see enclosed proxy form)4. By internet (see enclosed proxy form)	<p>You are a beneficial holder if your common shares are held in the name of nominee. That is, your share certificate was deposited with, or you purchased and continue to hold your common shares through, a bank, trust company, securities broker, trustee, or other institution.</p> <p><u>Voting Options</u></p> <ol style="list-style-type: none">1. In person at the AGSM (see below)2. By voting instruction form (see below)3. By telephone (see enclosed voting instruction form)4. By internet (see enclosed voting instruction form)
<p><u>Voting in Person</u></p> <p>If you plan to attend the AGSM and want to vote your common shares in person, do NOT complete or return the enclosed proxy. Your vote will be taken and counted at the AGSM. Please register with us when you arrive at the AGSM to ensure that your vote will be counted.</p>	<p><u>Voting in Person</u></p> <p>If you plan to attend the AGSM and wish to vote your common shares in person, insert your own name in the space on the enclosed voting instruction form. Then follow the signing and return instructions provided in that form. Your vote will be taken and counted at the AGSM, so do NOT indicate your votes on the form. Please register with</p>

Registered Shareholder Voting	Beneficial Shareholder Voting
<p data-bbox="220 289 402 319"><u>Voting by Proxy</u></p> <p data-bbox="220 323 812 747">Whether or not you attend the AGSM, you can appoint someone else to attend and vote as proxy holder. Use the enclosed proxy form to do this. The people named in the enclosed proxy are executives or the board of directors (“Directors”). <i>You have the right to choose another person to be your proxy holder by printing that person’s name in the space provided.</i> Then complete the rest of the proxy, sign it and return it. Your votes can only be counted if the person you appointed attends the AGSM and votes on your behalf. <i>If you have voted by proxy, you may NOT vote in person at the AGSM, unless you properly revoke your proxy (see below).</i></p> <p data-bbox="220 821 787 947">Return your completed proxy so that it arrives not less than 48 hours (excluding Saturdays, Sundays, and holidays) before the time set for the holding of the AGSM or any adjournment thereof.</p> <p data-bbox="220 1016 456 1045"><u>Revoking your Proxy</u></p> <p data-bbox="220 1050 812 1404"><i>You may revoke your proxy at any time before it is acted on.</i> To do so, you can deliver a written statement that you want to revoke your proxy (which includes another proper form of proxy with a later date) to our transfer agent, Computershare Trust Company of Canada (“Computershare”), in accordance with the instructions set out in the form of proxy provided not less than 48 hours (excluding Saturdays, Sundays, and holidays) before the time set for the holding of the AGSM or any adjournment thereof.</p> <p data-bbox="220 1444 803 1734">Or, you can revoke your proxy by delivering a properly executed instrument in writing at the registered office of the Corporation (attn: Harris Liontas) at any time up to and including the last business day preceding the day of the AGSM, or any adjournment thereof, or with the Chairperson of the AGSM on the day of the AGSM, or any adjournment thereof, and upon either such deposits, the proxy is revoked.</p>	<p data-bbox="837 222 1474 285">us when you arrive at the AGSM to ensure that your vote will be counted.</p> <p data-bbox="837 289 1219 319"><u>Voting by Voting Instruction Form</u></p> <p data-bbox="837 323 1474 779">Whether or not you attend the AGSM, you can appoint someone else to attend and vote as proxy holder. Use the enclosed voting instruction form to do this. The people named in the enclosed voting instruction form are executives or Directors. <i>You have the right to choose another person to be your proxy holder by printing that person’s name in the space provided.</i> Then complete the rest of the voting instruction form, sign it and return it. Your votes can only be counted if the person you appointed attends the AGSM and votes on your behalf. <i>If you have voted on the voting instruction form, NEITHER you nor your proxy holder may vote at the AGSM, unless you properly revoke your proxy (see below).</i></p> <p data-bbox="837 821 1474 978">Return your completed voting instruction form provided so that it arrives not less than 48 hours (excluding Saturdays, Sundays, and holidays) before the time set for the holding of the AGSM or any adjournment thereof so that your nominee has time to deliver your instructions.</p> <p data-bbox="837 1016 1073 1045"><u>Revoking your Proxy</u></p> <p data-bbox="837 1050 1474 1308"><i>You may revoke your proxy at any time before it is acted on.</i> Please follow the procedures provided by your nominee. Your nominee will likely need to receive your request to revoke your instructions not less than 48 hours (excluding Saturdays, Sundays and holidays) before the time set for the holding of the AGSM or any adjournment thereof in order for your nominee to have time to deliver your instructions to Computershare.</p>

Registered Shareholder Voting	Beneficial Shareholder Voting
<p><u>Mailing Address</u> If you wish to return your proxy by mail, please send to: Computershare ATTN: Proxy Department 320 Bay Street, 14th Floor Toronto, ON M5H 4A6</p>	<p><u>Mailing Address</u> If you wish to return your proxy by mail, please send to: Computershare ATTN: Proxy Department 320 Bay Street, 14th Floor Toronto, ON M5H 4A6</p>

Instructing your Proxyholder

You may indicate on your Proxy/Voting Instruction Form how you wish your proxyholder to vote your shares. To do this, simply mark the appropriate boxes on the form. If you do this, your proxyholder must vote your shares in accordance with the instructions you have given.

If you do not give any instructions as to how to vote on a particular issue to be decided at the AGSM, your proxyholder can vote your shares as he or she thinks fit. If you have appointed the persons designated in the form as your proxyholder they will, unless you give contrary instructions, vote your shares at the AGSM as follows:

- ✓ **FOR the election of the proposed nominees as Directors;**
- ✓ **FOR the re-appointment of Baker Tilly HMA LLP, as the auditor of Novra; and to authorize the directors to fix the remuneration to be paid to the auditor; and**
- ✓ **FOR the settlement of US \$3,200,000, or \$4,352,000 CAD based on an exchange rate of \$1.36, of the Company’s convertible notes (the “Debt”) through the issuance of 12,800,000 common shares of the Company at a deemed price \$0.34 CAD per share.**

For more information about these matters, see Part 3 – Matters to be Acted Upon at the AGSM. The enclosed form gives the persons named on it the authority to use their discretion in voting on amendments or variations to matters identified on the Notice of AGSM. At the time of printing this Circular, the management of Novra is not aware of any other matter to be presented for action at the meeting. If, however, other matters do properly come before the AGSM, the persons named on the enclosed form of proxy will vote on them in accordance with their best judgment, pursuant to the discretionary authority conferred by the form of proxy with respect to such matters.

WHAT IS OUR QUORUM?

Under our Bylaws, at least two shareholders must be present in person or represented by proxy holding or representing not less than 1/10th of the shares entitled to vote at the meeting before any action may validly be taken at the AGSM. If such a quorum is not present in person or by proxy, we will reschedule the AGSM.

HOW A VOTE IS PASSED

All of the matters that will come to a vote at the AGSM are ordinary resolutions and can be passed by a simple majority – that is, if more than half of the votes that are cast are in favour, then the resolution is approved.

PART 2 – AUTHORIZED CAPITAL, VOTING SHARES AND PRINCIPAL HOLDERS THEREOF

Novra has authorized capital of an unlimited number of common shares and an unlimited number of Class A preferred shares, all without par value. Each shareholder is entitled to one vote for each common share registered in his or her name at the close of business on May 6, 2026, the Record Date. According to Novra’s registrar and Computershare, 35,420,293 common shares were issued and outstanding on the Record Date, including 2,000,000 common shares that were issued to our subsidiary, Wegener Corporation as part the 51.6% controlling interest acquisition on December 29, 2017.

To the knowledge of our Directors and executive officers, the following table sets forth the names of each person who beneficially owns, directly or indirectly, or exercises control or direction 10% or more of our voting common shares:

Name	Number of common shares ⁽¹⁾	Percentage of issued shares
Harris Liontas	5,437,614	15.4%

(1) Information as to ownership of shares has been taken from the list of registered shareholders maintained by Computershare or has been provided by the individuals.

PART 3 – MATTERS TO BE ACTED UPON AT THE AGSM

FINANCIAL STATEMENTS

The audited financial statements of Novra for the year ended December 31, 2025, and the auditor’s report thereon will be placed before you at the AGSM for your consideration. These financial statements have been approved by the Board of Directors and filed with the Canadian System for Electronic Document Analysis and Retrieval (SEDAR+) at www.sedarplus.ca and can be viewed there.

ELECTION OF DIRECTORS

Directors of Novra are elected for a term of one year. The term of office of each of the nominees proposed for re-election as a Director will expire at the meeting, and each of them, if elected, will serve until the close of the next AGSM, unless he resigns or otherwise vacates office before that time. Pursuant to the *Canada Business Corporations Act* and the requirements of the TSX Venture Exchange (the “**TSXV**”), Novra must have a minimum of three Directors, two of whom are neither officers nor employees of Novra. We currently have four Directors. The Company is including one new nominee, which will increase the board from four to five Directors for the coming year.

Director Nominee Information

The following table list the nominees proposed for election as Directors of Novra, together with the number of common shares that are beneficially owned, directly or indirectly, or over which control or direction is exercised, by each nominee.

Name and place of residence	Present Position and Offices	Principal Occupation for Last 5 Years	Director since	Number of shares
Rodney Allan Ontario, Canada	None	President of Novra since 2024; General Manager, International Datacasting Corp (IDC) prior	NA	Nil
Dr. Mohamed (Moe) Barakat Ontario, Canada	Director; Member of Audit Committee and Compensation Committee	Retired	September 1, 2024	2,616,185 ⁽²⁾
George (Brian) Eckhardt Manitoba, Canada	Director, acting in the capacity of CFO	President and CEO of Infomagnetics Technologies Corp.	June 28, 2018	428,571 ⁽¹⁾
Harris Liontas Manitoba, Canada	CEO and Director; Member of Audit Committee	CEO of Novra	June 6, 2001	5,437,614 ⁽¹⁾
Kelvin Maloney Manitoba, Canada	Director; Member of Audit Committee and Compensation Committee	Director of Corporate Development, Paterson Globalfoods	June 24, 2005	Nil

⁽¹⁾ 5,437,614 includes 2,500,000 common shares that are held by InfoMagnetics Technologies Inc. ("IMT"). Mr. Liontas is a controlling shareholder of IMT. George (Brian) Eckhardt is also a shareholder of IMT and is its President and CEO

⁽²⁾ 2,616,185 includes 1,233,270 common shares held by Dr. Barakat's spouse.

The information as to shares beneficially owned in the above table has been provided by the respective individuals.

Each of the above nominees has agreed to stand for election or re-election and we are not aware of any intention of any of them not to do so. If, however, one or more of them should become unable to stand for election or re-election, it is likely that one or more other persons would be nominated at the meeting for election and, in that event, the persons designated in the form of proxy will vote in their discretion for a substitute nominee.

Cease Trade Orders and Bankruptcy

On September 12, 2024 trading of the Company's shares on the TSXV was halted by the Canadian Investment Regulatory Organization (CIRO), pending clarification of a news release that was made on September 10 to disclose a convertible loan agreement. The exchange informed the company that they

had halted trading in the stock until such time that disclosure met exchange requirements for disclosure of such a transaction. Novra released additional information on December 19, 2024 and the stock resumed trading on the TSXV December 24, 2024. Related disclosures are available on SEDAR+ at www.sedarplus.ca. Novra has not been subject, within the ten years prior to the date of this circular, to any other cease trade or similar order that denied it access to any exemption under securities legislation, for a period of more than 30 consecutive days.

As at the date of this Circular, no proposed nominee listed above is, or has been, within ten years before the date of this Circular, a director or executive officer of any other company that, while that person was acting in that capacity: was the subject of a cease trade or similar order or an order that denied the relevant company access to any exemption under securities legislation, for a period of more than 30 consecutive days;

As at the date of this Circular, no proposed nominee listed above is, or has been, within ten years before the date of this Circular, a director or executive officer of any company (including Novra) that, while that person was acting in that capacity: was subject to an event that resulted, after the director or executive officer ceased to be director or executive officer, in the company being the subject of a cease trade or similar order or an order that denied the relevant company access to any exemption under securities legislation, for a period or more than 30 consecutive days; or within a year of that person ceasing to act in that capacity, became bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency or was subject to or instituted any proceedings, arrangement or compromise with creditors or had a receiver, receiver manager or trustee appointed to hold its assets.

Personal Bankruptcy

As at the date of this Circular, no proposed nominee listed above has, within the ten years before the date of this Circular, become bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency, or become subject to or instituted any proceedings, arrangement or compromise with creditors, or had a receiver, receiver manager or trustee appointed to hold the assets of the proposed director.

Recommendation

The Board recommends that shareholders vote **FOR** the nominees for election as Directors.

APPOINTMENT OF THE AUDITOR

The Board proposes to re-appoint Baker Tilly HMA LLP (“Baker Tilly”), Chartered Professional Accountants of Winnipeg, Manitoba, as Novra’s independent auditors for the ensuring year. See under Part 5 for total fees paid/accrued to this firm in 2025 and 2024. Baker Tilly has served as Novra’s auditors since fiscal 2001.

Recommendation

The Board recommends that shareholders vote **FOR** the re-appointment of Baker Tilly as Novra’s auditor for the ensuing year and grant the Board the authority to determine the remuneration to be paid to the auditor.

APPROVAL OF DEBT SETTLEMENT

Overview

At the AGSM, Shareholders will be asked to consider and, if deemed advisable, pass an ordinary resolution approving the settlement of an aggregate of US \$3,200,000, or \$4,352,000 CAD based on an exchange rate of \$1.36, of the Company’s convertible notes through the issuance of 12,800,000 common shares of the Company (the “**Settlement Shares**”) at a deemed price of \$0.34 per common share (the “**Debt Settlement**”).

The Debt proposed to be settled pursuant to the Debt Settlement is owing to SNAPS Holding Company (the “**Creditor**” or “**SNAPS**”) and arose from unsecured working capital advances in the form of a convertible note, the closing of which was previously announced on May 12, 2026. The Company determined that it is in the best interests of the Company to settle the Debt through the issuance of common shares to preserve cash for operations, reduce outstanding liabilities and improve the Company’s financial position.

The deemed issue price of \$0.34 per Settlement Share was negotiated at arm’s length, representing a superior valuation compared to Novra’s closing stock price of \$0.07 on the TSXV on January 29, 2026, the date of the original loan agreement and \$0.125 on April 20, 2026, the date of the most recent amendment. The TSXV provided final acceptance for this private placement on May 22, 2026. In accordance with applicable Canadian securities laws, the Settlement Shares will be subject to a hold period of four months and one day from May 12, 2026, the date the associated convertible loan closed.

In addition to the above Debt Settlement, the Company previously received US \$500,000 of convertible notes (“**Additional Debt**”) from the Creditor in June 2025. The Company received acceptance from the TSXV to settle US\$500,000, or \$681,000 CAD based on an exchange rate of \$1.37, through the issuance of 2,002,944 common shares of the Company at \$0.34 per share (the “**Additional Settlement Shares**”). The Company intends to complete this transaction shortly. As of the date of this Circular, the Creditor owns no common shares in Novra. Given the TSXV’s prior acceptance, there is no required resolution to approve this share-for-debt settlement. The interest associated with this Additional Debt will be forgiven upon issuance of the shares, in accordance with the agreement.

Effect of the Debt Settlement on Share Capital

As of the date of this Circular, the Company has 35,420,293 common shares issued and outstanding.

The following table sets out the pro forma impact of the Settlement Shares and Additional Settlement Shares on the Company’s share capital:

Item	Amount
Common shares currently issued and outstanding	35,420,293
Settlement Shares and Additional Settlement Shares to be issued to SNAPS	14,802,944
Common shares outstanding after completion	50,233.237
Increase in issued shares vs. current outstanding	41.8%
Dilution to existing Shareholders	29.5%

Following completion of the above common share issuances, SNAPS will beneficially own, or exercise control or direction over, 29.5% of Novra's issued and outstanding common shares. **Accordingly, SNAPS will become a "Control Person" of the Company for purposes of TSXV Policy 4.3.**

Purpose and Business Rationale

The Board of Directors believes that the Debt Settlement is in the best interests of the Company for the following reasons:

- the Debt Settlement will prevent treating the US \$3,200,000, or \$4,352,000 CAD, as a liability on the Company's balance sheet (in addition to the US \$500,000, or \$681.0007,6500 CAD debt for share conversion, as previously accepted by the TSXV);
- the Debt Settlement will preserve cash resources that would otherwise be required to satisfy the Debt;
- the Debt Settlement will improve the Company's working capital position; and
- the Debt Settlement will be done at a substantial favourable debt to equity conversion rate of \$0.34 CAD per share. As of the date of this Circular, the Company's common stock closed at \$0.16 CAD per share on the TSXV.

If the Debt Settlement is not completed, the Debt will be treated as an outstanding liability in accordance with its existing terms and the Company will be required to satisfy the Debt in cash or seek alternative settlement arrangements.

Board Approval and Recommendation

The Board of Directors has reviewed and approved the Debt Settlement and has determined that the Debt Settlement is in the best interests of the Company. In reaching its determination, the Board considered the amount of indebtedness being settled, the benefit of preserving the Company's cash resources, the favourable debt to equity conversion rate, the positive impact on the Company's balance sheet and working capital position, and the consequences of the creditor becoming a Control Person of the Company upon completion of the Debt Settlement.

Accordingly, the Board of Directors unanimously recommends that Shareholders vote **FOR** the resolution approving the Debt Settlement.

Information on Additional Loan Agreement

As announced on February 11, 2026, the Company entered into a two-year convertible loan agreement with SNAPS in the amount of US \$5,300,000 (or \$7,200,000 CAD based on an exchange rate of \$1.37), bearing interest at 1% per annum (“**Future Loan**”). As of the date of this Circular, the Company has not received the funding; however, SNAPS expects to provide the funds on or before September 30, 2026. The Loan principal can be converted by either party at any time to Novra common shares with a minimum price of \$0.34 CAD and not less than the Market Price at the Price Reservation Data once funds are received, subject to TSXV approval (“**Future Deemed Price**”).

After closing of the Future Loan, if the Company determines that it is in the best interests of the Company to settle the Debt through the issuance of common shares and the TSXV accepts the transaction, Shareholders will be asked to consider and, if deemed advisable, pass another resolution authorizing the Company to settle the Future Loan through the issuance of common shares of the Company, subject to the Future Deemed Price, in the event that it would lead to a change in control of the Company.

OTHER BUSINESS

Management knows of no matters to come before the AGSM other than the matters referred to the Notice of the AGSM. However, if any other matters which are not now known to Management should properly come before the AGSM, the shares represented by proxies in favour of Management nominees will be voted on such matters in accordance with the best judgment of the proxy nominees.

PART 4 – INFORMATION CONCERNING NOVRA

DIRECTOR AND EXECUTIVE COMPENSATION

Novra is a venture issuer and is disclosing its executive compensation in accordance with Form 51-102F6V, Statement of Executive Compensation – Venture Issuers.

The following persons are considered the “Named Executive Officers” or “NEOs” for the purposes of the disclosure:

- (a) Novra’s CEO, including an individual performing functions similar to a chief executive officer;
- (b) Novra’s CFO, including an individual performing functions similar to a chief financial officer;
- (c) The most highly compensated executive officer, other than the CEO or the CFO, at the end of the most recently financial year whose total compensation was more than \$150,000; as determined in accordance with Form 51-102F6V, for that financial year; and
- (d) Each individual who would be named executive officer under paragraph (c) but for the fact that the individual was not an executive officer of Novra, and was not acting in a similar capacity, at the end of that financial year.

Based on the above definition, we have determined the following persons to be Novra’s NEOs for its financial year ended December 31, 2025:

- Harris Liontas – Chief Executive Officer; and
- George (Brian) Eckhardt – Director, acting in the capacity of CFO,

The following table discloses the compensation paid and accrued by Novra to the NEOs and Directors for the two most recently completed financial years, excluding compensation securities.

Table of Compensation, excluding Compensation Securities						
Name and Position	Year	Salary, consulting fee, retainer, or commission (\$)	Bonus (\$)	Directors Fees (\$)	Value of other compensation (\$)	Total compensation (\$)
Harris Liontas ⁽¹⁾ CEO	2025	200,000	-	-	-	200,000
	2024	15,000	-	-	-	15,000
George (Brian) Eckhardt Director & CFO ⁽²⁾	2025	-	-	4,000	-	4,000
	2024	-	-	4,000	-	4,000
Moe Barakat Director	2025			4,000		4,000
	2024			1,000		1,000
Kelvin Maloney Director	2025	-	-	4,000	-	4,000
	2024	-	-	4,000	-	4,000
Peter J. Wintemute Former Director	2025			-		-
	2024			3,000		3,000

(1) Mr. Liontas’s base salary was \$200,000 in 2025 and 2024. However, only \$15,000 of this was paid each year. In 2025, the remainder was accrued. In 2024, \$185,000 was forgiven by Mr. Liontas.

(2) Mr. Eckhardt is a board Director. He also acts in the capacity of CFO. He receives no additional compensation in this role and is not an employee of Novra.

(3) There was no other compensation in 2025 or 2024. From time to time the value of other compensation may include a Company matching contribution, up to a specific limit, to the NEO’s RRSP.

Compensation Securities

On April 28, 2017, the Board of Directors approved the 2017 Stock Option Plan as described under SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS below. Additionally, on April 28, 2017 the Board approved the following stock options grant for the current NEOs and Directors under the 2017 Stock Option Plan:

- Harris Liontas: 120,000
- Kelvin Maloney: 120,000

Based on the TSX-V's approval date of May 9, 2017, the exercise price for the above options was set at \$0.12 each and these options were set to expire in seven years. The vesting provision for these options was as follows:

- 20% on June 30, 2017;
- 20% on December 31, 2017;
- 20% on December 31, 2018;
- 20% on December 31, 2019; and
- 20% on December 31, 2020.

None of these options were exercised by current Directors or NEOs. All unexercised options expired on May 9, 2024.

Oversight and Description of Director and NEO Compensation

The Board's Compensation Committee provides oversight over compensation for Directors and NEOs. See Part 6 – Corporate Governance.

Director compensation:

The Board is responsible for determining the compensation level for the external Directors. For the year ended December 31, 2025, the Board maintained the quarterly fee at \$1,000. Additionally, we reimburse Directors for reasonable business-related expenses.

While serving as Novra's CEO, Mr. Lontas does not receive additional compensation for serving as a Director.

NEO compensation:

The Board is responsible for determining and approving all forms of compensation for Novra's CEO as well as for reviewing the CEO's recommendations for the compensation of any other NEOs, to ensure such arrangements reflect the responsibilities and risks associated with each position. When determining the compensation for its CEO and other NEOs, the Board considers the following:

- recruiting and retaining executives critical to the success of Novra and the enhancement of shareholder value;
- providing fair and competitive compensation, based on comparable publicly traded Canadian companies, that is also financially affordable to Novra;
- creating among employees a sense of ownership in Novra, thus aligning the interest of employees with those of the shareholders; and
- rewarding performance, both on an individual basis and with respect to operations in general, through incentives that are linked to the company's business strategy and its ability to pay.

To achieve these objectives, the compensation paid to the Novra's CEO and other NEOs consists of two components: i) base salary; and ii) long-term incentive in the form of stock options. The approval of the CEO's compensation is made by the two independent Directors.

We have not entered into an employment agreement with Mr. Liontas in 2025. Mr. Liontas voluntarily agreed to allow Novra to accrue all but \$15,000 of his base salary in each of 2024 and 2025. He also agreed to forgive \$185,000 of his base salary earned during 2024. He further agreed to continue to carry forward unpaid compensation from prior years to preserve liquidity in Novra. At December 31, 2025, \$1.31 million was due to Mr. Liontas.

In February 2018 the Board set Mr. Liontas's base annual salary at \$200,000. The Director's also approved a CEO performance bonus of \$1.3M contingent on any one or more of the following future conditions being met, at which point the performance bonus would immediately become due:

1. Termination of the CEO's employment
2. Change of Control as defined by TSX Policy 1.1
3. Change of Management as defined by TSX Policy 1.1
4. Any shareholder or group of shareholders operating in tandem acquiring 20% or more of Novra's voting shares.
5. Any action that the Board deems as a hostile takeover of Novra
6. Any action that the Board deems as a hostile action to control the Board
7. Novra being acquired by another company
8. Market capitalization reaches \$10,000,000 CND dollars

The CEO, at his discretion, has the option to receive the performance bonus in any one or combination of the following three forms, at the time the performance bonus is issued:

1. Accrued liability, in which case the performance bonus may not be immediately paid out.
2. Immediate payment
3. Any part of the bonus can be converted to Novra shares, at a value of the current market price less a 25% discount, subject to TSX approval. This option is not available if the trigger condition is "7" above (Novra is acquired).

We have no compensatory plan or arrangement in place to compensate NEOs in the event of a termination of employment due to resignation or retirement.

SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS

On April 28, 2017, the Board of Directors approved the 2017 Stock Option Plan in order to retain and attract executives, directors, and key employees and align their interests with those of Novra's shareholders to generate an attractive return over the long-term. The new plan replaces and terminates the former option plan in which there was no outstanding option. The criteria used to determine eligibility for granting stock

options, including the exercise price and vesting provisions, is at the discretion of the Board subject to complying with the TSX-V rules. The 2017 Stock Option Plan was approved by the TSX-V on May 9, 2017.

INDEBTEDNESS OF DIRECTORS AND OFFICERS

No individual who is, or at any time during the most recently completed financial year was, a Director or executive officer of Novra, nor any proposed nominee for election as a Director, nor any associate of any of them:

- a) is, or at any time since the beginning of the most recently completed financial year of Novra has been, indebted to Novra or any of its subsidiaries; or
- b) was indebted to another entity, which such indebtedness is, or was at any time during the most recently completed financial year of Novra, the subject of a guarantee, support agreement, letter of credit, or other similar arrangement or understanding provided by Novra or any of its subsidiaries.

INTEREST OF INSIDERS IN MATERIAL TRANSACTIONS

Except as otherwise set out herein, no proposed nominees for election as Directors, and no executive officer of Novra who has served in such capacity since January 1, 2025, and no shareholder holding of record or beneficially, directly or indirectly, more than 10% of Novra's outstanding common shares, and none of the respective associates or affiliates of any of the foregoing, had any interest in any transaction with Novra or in any proposed transaction since January 1, 2025, that has materially affected Novra, or is likely to do so.

On June 16, 2017, a \$300,000 convertible note with IMT, a company controlled by Mr. Liontas, was converted to 2,500,000 common shares. Further, IMT has provided additional financing in the form of unsecured promissory notes – see Note 16 (d) of the December 31, 2025 Consolidated Financial Statements for further details. As of the date of this circular, all such unsecured promissory notes have been repaid in full.

INTEREST OF CERTAIN PERSONS IN MATTERS TO BE ACTED UPON

Other than as described elsewhere herein, none of the Directors or NEOs of Novra, nor any of their known associates, has any substantial interest, direct or indirect, by way of beneficial ownership of securities or otherwise, in any matter to be acted upon at the AGSM.

MANAGEMENT CONTRACTS

The management functions of Novra are performed by our directors or executive officers and we have no management agreements or arrangements under which such management functions are performed by persons other than the directors or executive officers of Novra.

DIVERSITY DISCLOSURE

As of the date of this information circular, the Board of Directors and Senior Management Team of Novra Technologies Inc. include:

Role	Total	Women		Indigenous Peoples		Persons with Disabilities		Visible Minorities		Individuals in more than one category
	Number	Number	Percent	Number	Percent	Number	Percent	Number	Percent	
Board of Directors	4	0	0%	0	0%	0	0%	0	0%	0
Senior Management*	5	2	40%	0	0%	0	0%	0	0%	0

* CEO, CFO, President, EVP of Business Operations, VP of Sales & Marketing. Does not include internal management at the controlling interest subsidiary.

The Board does not, at present, have a written policy relating to the identification and nomination of Directors from the designated groups nor does it have formal term limits in place. It will consider implementing such in the future, should circumstances warrant. Based on Novra's size, its stage of development and the limited number of individuals on the Board and in Senior Management, the Board considers a formal policy to be inappropriate at this time. The Board considers the level of representation of designated groups on the board and in senior management on an ad hoc basis and plans to continue evaluating and promoting its own and Senior Management diversity on an ad hoc basis. No formal targets have been defined at this time.

ADDITIONAL INFORMATION

Our Consolidated Financial Statements and Management's Discussion and Analysis for the year ended December 31, 2025, which have been filed with SEDAR+ at www.sedarplus.ca, provide additional financial information about Novra.

PART 5 – AUDIT COMMITTEE INFORMATION

AUDIT COMMITTEE CHARTER

The Charter for the Audit Committee of the Board of Directors of Novra is attached to this Circular as Appendix A.

AUDIT COMMITTEE COMPOSITION AND BACKGROUND

Dr. Barakat and Messrs. Lontas and Maloney are members of Novra's Audit Committee.

As an issuer listed on the TSX-V, relying on the exemption available in section 6.1 of National Instrument 52-110 – Audit Committees ("NI 52-110"), Novra is exempt from the requirements, among others, that all of the members of the Audit Committee be "independent" and "financially literate".

Dr. Barakat and Mr. Maloney are considered “independent” as that term is defined in NI-52-110 and accordingly the majority of the Audit Committee members are independent. Further, all three of the Audit Committee members are “financially literate” i.e. have the ability to read and understand financial statements that present a breadth and level of complexity of accounting issues that are generally comparable to the breadth and complexity of the issues that can reasonably be expected to be raised by Novra’s consolidated financial statements.

RELEVANT EDUCATION AND EXPERIENCE

All of the Audit Committee members are senior-level businesspeople with experience in financial matters; each has a broad understanding of accounting principles used to prepare financial statements and varied experience as to general application of such accounting principles, as well as the internal controls and procedures necessary for financial reporting, garnered from working in their individual fields of endeavor. In addition, certain of the members of the Audit Committee have knowledge of the role of an Audit Committee in the realm of reporting companies from their experience as directors of companies other than Novra.

The following is a brief bio for the two independent Audit Committee members:

Kelvin Maloney

Kelvin is currently the Director of Corporate Development, Paterson Globalfoods. Immediately prior to this he was an Investment Manager with FCC Ventures. Kelvin has an MBA and Bachelor of Science in Computer Engineering, both from the University of Manitoba. He has experience in a broad range of industries including information technology, biotechnology, primary and value-added agriculture, manufacturing and financial services. Earlier in his professional career, Kelvin worked for the management-consulting arm of a major international accounting firm. At this position, he focused mainly in the areas of financial modeling, business valuations and strategic planning. Kelvin holds the Chartered Financial Analyst (CFA) designation and is a member of the CFA Institute and the Winnipeg Society of Financial Analysts.

Moe Barakat

Dr. Barakat, B. Sc., M. Sc., Ph.D is an accomplished entrepreneur and business leader who focuses on wireless communications and information system. He was the co-founder and President of InfoMagnetics Technologies (IMT) from 1991 to 2000 and Chairman of the Board from 1991 up until his retirement in 2020. Dr. Barakat was also Novra’s first President & CEO (2000 – 2001) and a director on Novra’s Board from 2000 to 2006. He was an adjunct professor in the Department of Electrical and Computer Engineering at the University of Manitoba from 1983 to 2010. Dr. Barakat was the co-founder CEO of SpectraWorks Inc. and the chairman of IMT Communications Systems Inc. He has also held senior positions with a range of other organizations, including National

Research Council of Canada, Norsat International Inc., Telecommunications Laboratory TRILabs Inc., and International Organization for Standardization (ISO), among others.

EXTERNAL AUDITOR SERVICE FEES

The aggregate amounts paid or accrued by Novra with respect to fees payable to Baker Tilly, our current external auditor, for audit, tax and other services in each of the last two fiscal years were as follows:

	2025	2024
Audit fees ⁽¹⁾	\$130,000	\$130,000
Audit-related fees ⁽²⁾	-	-
Tax fees ⁽³⁾	\$18,000	\$18,000
All other fees ⁽⁴⁾	-	-
Total	\$148,000	\$148,000

(1) Include the aggregate professional fees paid for the audit of the annual consolidated financial statements.

(2) Include the aggregate fees paid for services related to the audit services, including bill-through of external inventory observation fees.

(3) Include the aggregate fees paid for tax compliance, advice, planning and advisory services.

(4) Include the aggregate fees paid for all other services other than those presented above.

The Audit Committee pre-approves all non-audit services provided to Novra by its external auditors.

PART 6 – CORPORATE GOVERNANCE

The Board believes corporate governance is essential to the effective and efficient operation of Novra. The practice of corporate governance should reflect Novra’s circumstances, having always as its ultimate objective, the best long-term interests of Novra and the enhancement of value for all shareholders.

The following is a summary of our approach to corporate governance.

Composition of the Board

The Board is currently composed of four Directors (see Part 3 – Matters to be Acted Upon at AGSM).

The Board has reviewed the independence of each Director based on the definition in NI 58-101. After reviewing the roles and relationships of each of the Directors, the Board has determined that two directors of the Board are independent - both Dr. Barakat and Mr. Maloney are independent from Novra. Harris Lontas, by virtue of being the CEO of Novra, is the only current Director who is a member of management and, as such, determined to be non-independent. Brian Eckhardt, by virtue of acting in the capacity of CFO of Novra, is an Officer of Novra and, as such, determined to be non-independent.

As of the date of this Circular, none of the current Directors standing for re-election are directors of other reporting issuers. Further, collectively the Board owns or controls approximately 25% of the outstanding common shares of Novra as of May 22, 2025 and accordingly, it believes that the interest of the management and shareholders is aligned.

Orientation and Continuing Education

The Board is responsible for the orientation and education of new recruits to the Board. Prior to joining the Board, each new director will meet with the Chair of the Board and the Chief Executive Officer of Novra. Each such officer shall be responsible for outlining the business and prospects of Novra, both positive and negative, with a view to ensuring that the new Director is properly informed to commence his or her duties as a Director. Each new Director will also be given the opportunity to meet with Novra's external auditor and legal counsel, as may be required.

Code of Business Ethics

To date, the Board has not adopted a formal written Code of Business Conduct and Ethics. However, the current limited size of Novra's operations and the small number of officers and employees allow the independent Directors to monitor on an ongoing basis the activities of management and to ensure that the highest standard of ethical conduct is maintained. As Novra grows in size and scope, the Board anticipates that it will formulate and implement a formal Code of Business Conduct and Ethics.

Nomination of Directors

The Board determines new nominees to the Board, although a formal process has not been adopted. The nominees are generally the result of recruitment efforts by the Board, including both formal and informal discussions among Directors and the CEO. The current size of the Board is such that the entire Board takes responsibility for selecting new Directors and assessing current Directors. Proposed directors' credentials are reviewed with one or more Directors prior to the proposed director's nomination.

Assessments

The Board does not, at present, have a formal process in place for assessing the effectiveness of the Board of Directors as a whole, its committees or individual Directors, but will consider implementing one in the future should circumstances warrant. Based on Novra's size, its stage of development and the limited number of individuals on the Board, the Board considers a formal assessment process to be inappropriate at this time. The Board plans to continue evaluating its own effectiveness on an ad hoc basis.

Committees of the Board of Directors

The Board of Directors of Novra has appointed two committees - an Audit Committee and a Compensation Committee. See Part 5 – Audit Committee Information.

The Compensation Committee is comprised of only independent Directors – Dr. Barakat and Mr. Maloney - and shall assist the Board in: (i) determining appropriate compensation levels for the Novra's NEOs; (ii) evaluating officer and director compensation plans, policies, and programs; and (iii) reviewing benefit plans for officers and employees.

In discharging its role, the Compensation Committee is empowered to investigate any matter brought to its attention with access to all books, records, facilities, and personnel of Novra. The Compensation Committee has the power to retain outside counsel, compensation consultants, or other experts based on an approved budget. The Compensation Committee shall have the sole authority to retain, compensate, terminate, and oversee the executive compensation consultants, who shall be accountable ultimately to the committee.

BOARD APPROVAL

The contents and the sending of this Circular have been approved by the Board.

Winnipeg, Manitoba

May 25, 2026

APPENDIX A - CHARTER FOR THE AUDIT COMMITTEE

1. Purpose

- 1.1. The Audit Committee is ultimately responsible for the policies and practices relating to integrity of financial and regulatory reporting, as well as internal controls to achieve the objectives of safeguarding of corporate assets; reliability of information; and compliance with policies and laws. Within this mandate, the Audit Committee's role is to:
 - (a) support the Board of Directors in meeting its responsibilities to shareholders;
 - (b) enhance the independence of the external auditor;
 - (c) facilitate effective communications between management and the external auditor and provide a link between the external auditor and the Board of Directors;
 - (d) increase the credibility and objectivity of the Corporation's financial reports and public disclosure.
- 1.2. The Audit Committee makes recommendations to the Board of Directors regarding items relating to financial and regulatory reporting and the system of internal controls following the execution of the Committee's responsibilities as described herein.
- 1.3. The Audit Committee will undertake those specific duties and responsibilities listed below and such other duties as the Board of Directors from time to time prescribe.

2. Membership

- 2.1. Each member of the Audit Committee must be a director of the Corporation.
- 2.2. The Audit Committee will consist of at least three members, the majority of whom are neither officers nor employees of the Corporation or any of its affiliates and are considered "independent" as that term is defined in Multilateral Instrument 52-110.
- 2.3. The members of the Audit Committee will serve at the discretion of the Board of Directors.

3. Authority

- 3.1. In addition to all authority required to carry out the duties and responsibilities included in this charter, the Audit Committee has specific authority to:

- (a) engage, and set and pay the compensation for, independent counsel and other advisors as it determines necessary to carry out its duties and responsibilities; and
- (b) communicate directly with management and any internal auditor, and with the external auditor without management involvement.
- (c) approve interim financial statements and interim MD&A on behalf of the Board of Directors.

4. Duties and Responsibilities

4.1. The duties and responsibilities of the Audit Committee include:

- (a) recommending to the Board of Directors the external auditor to be nominated by the Board of Directors;
- (b) recommending to the Board of Directors the compensation of the external auditor;
- (c) reviewing the external auditor's audit plan, fee schedule and any related services proposals;
- (d) overseeing the work of the external auditor;
- (e) ensuring that the external auditor is in good standing with the Canadian Public Accountability Board and will enquire if there are any sanctions imposed by the CPAB on the external auditor;
- (f) ensuring that the external auditor meets the rotation requirements for partners and staff on the Corporation's audits;
- (g) reviewing and discussing with management and the external auditor the annual audited financial statements, including discussion of material transactions with related parties, accounting policies, as well as the external auditor's written communications to the Committee and to management;
- (h) reviewing the external auditor's report, audit results and financial statements;
- (i) reporting on and recommending to the Board of Directors the annual financial statements and the external auditor's report on those financial statements, prior to Board approval and dissemination of financial statements to shareholders and the public;
- (j) reviewing financial statements, MD&A and annual and interim earnings press releases prior to public disclosure of this information;

- (k) Ensure the adequacy of the Corporation's system of internal accounting controls and internal audit process obtaining from the external auditor summaries and recommendations for improvement of such internal accounting controls;
- (l) resolving disputes between management and the external auditor regarding financial reporting;
- (m) establishing procedures for:
 - (i) the receipt, retention and treatment of complaints received by the Corporation from employees and others regarding accounting, internal accounting controls or auditing matters and questionable practices relating thereto; and
 - (ii) the confidential, anonymous submission by employees of the Corporation of concerns regarding questionable accounting or auditing matters.
- (n) reviewing and approving the Corporation's hiring policies with respect to partners or employees (or former partners or employees) of either a former or the present external auditor;
- (o) pre-approving all non-audit services to be provided to the Corporation or any subsidiaries by the Corporation's external auditor;
- (p) overseeing compliance with regulatory authority requirements for disclosure of external auditor services and Audit Committee activities.

4.2. The Audit Committee will report to the Board regarding the Committee's examinations and recommendations.

5. Meetings

5.1. The quorum for a meeting of the Audit Committee is a majority of the members of the Committee who are not officers or employees of the Corporation or of an affiliate of the Corporation.

5.2. The members of the Audit Committee must elect a chair from among their number and may determine their own procedures.

- 5.3. The Audit Committee may establish its own schedule that it will provide to the Board of Directors in advance.
- 5.4. The external auditor is entitled to receive reasonable notice of every meeting of the Audit Committee and to attend and be heard thereat.
- 5.5. A member of the Audit Committee or the external auditor may call a meeting of the Audit Committee.
- 5.6. The Audit Committee will meet separately with the President and separately with the Chief Financial Officer of the Corporation at least annually to review the financial affairs of the Corporation.
- 5.7. The Audit Committee will meet with the external auditor of the Corporation at such time(s) as it deems appropriate, to review the external auditor's examination and report.
- 5.8. The chair of the Audit Committee must convene a meeting of the Audit Committee at the request of the external auditor to consider any matter that the auditor believes should be brought to the attention of the Board of Directors or the shareholders.

6. Reports

- 6.1. The Audit Committee will record its recommendations to the Board in written form which will be incorporated as a part of the minutes of the Board of Directors' meeting at which those recommendations are presented.

7. Minutes

- 7.1. The Audit Committee will maintain written minutes of its meetings, which minutes will be filed with the minutes of the meetings of the Board of Directors.

THIS PAGE INTENTIONALLY LEFT BLANK

